Carvedilol Tablet, Film Coated
Product Images NDC 43063-833

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 43063-833). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063833 Label (43063833)

Carvedilol USP 6.25 mg oral film-coated tablets packaging label for 60 tablets, manufactured by PD-Rx Pharmaceuticals, Inc. The label includes dosage strength, quantity, lot number J20C25, expiration date 10/2022, and standard warnings to keep out of reach of children and to consult a doctor for side effects. The label is bilingual with instructions in English and Spanish.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A line graph labeled 'Survival Analysis for COPERNICUS (Intent-to-Treat)' showing percentage mortality over months. The graph compares two groups, Placebo and Carvedilol, with mortality increasing over time for both but at different rates. Statistical significance is indicated by a p-value of 0.004.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot titled 'Effects on Mortality for Subgroups in COPERNICUS' showing hazard ratios for various patient subgroups, including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, spironolactone use, and overall patients. Each subgroup is represented by a point estimate and confidence intervals plotted along a horizontal axis ranging from 0 to 2 hazard ratio.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis line graph comparing mortality rates over 24 months between placebo and Carvedilol treatment groups from the CAPRICORN study. The y-axis shows percentage mortality, and the x-axis shows time in months, with Carvedilol showing lower mortality than placebo and a P-value of 0.03.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A figure titled 'Effects on Mortality for Subgroups in CAPRICORN' presenting two forest plots illustrating hazard ratios for mortality across various patient subgroups. Subgroups include age, gender, timing post-myocardial infarction, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA status, heart failure history, use of diuretics, angina presence, hypertension, diabetes, and heart rate. Each subgroup is shown with a point estimate and confidence intervals along a hazard ratio scale from 0.4 to 1.3.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure of Carvedilol showing its molecular arrangement with functional groups including hydroxyl and methoxy substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.